Keywords
Brain-gut bacterial axis
Trimebutine
Berberine
Submitted : 2025-06-07
Accepted : 2025-06-22
Published : 2025-07-07
Abstract
This study explored the therapeutic effect of trimebutine maleate dispersible tablets combined with berberine on PI-IBS rats with liver depression and spleen deficiency. Fifty male rats were divided into five groups: normal, model, berberine (XB), trimebutine (QM), and combination (XB+QM). The PI-IBS model was established using maternal separation, TNBS perfusion, and chronic restraint. After 20 days of drug intervention, DAI, CMDI, TDI, AWR scores, histopathology, and expression levels of c-Fos, VIP, NOS, and CHAT in the hippocampus and colon were assessed. The model group showed significant gut and brain changes, while the combination group (XB+QM) improved fecal characteristics, reduced inflammation, regulated brain-gut peptide expression, and alleviated visceral hypersensitivity and colon tissue damage (P < 0.05).
References
Drossman DA, Hasler WL, 2016, Rome IV–Functional GI Disorders: Disorders of Gut–Brain Interaction. Gastroenterology, 150(6): 1257–1261. doi: 10.1053/j.gastro.2016.03.035.
Zhang L, Duan L, Liu Y, et al., 2014, A Meta-Analysis of the Prevalence and Risk Factors of Irritable Bowel Syndrome in Chinese Community. Zhonghua Nei Ke Za Zhi, 53(12): 969.
Sadeghi A, Biglari M, Moghaddam SN, 2019, Post-Infectious Irritable Bowel Syndrome: A Narrative Review. Middle East Journal of Digestive Diseases, 11(2): 69.
Lee JY, Kim N, Park JH, et al., 2020, Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex. Journal of Neurogastroenterology and Motility, 26(1): 106.
Mukhtar K, Nawaz H, Abid S, 2019, Functional Gastrointestinal Disorders and Gut–Brain Axis: What Does the Future Hold? World Journal of Gastroenterology, 25(5): 552.
Barbara G, Grover M, Bercik P, et al., 2019, Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology, 156(1): 46–58.
Hellstrom PM, 2019, Pathophysiology of the Irritable Bowel Syndrome – Reflections of Today. Best Practice & Research Clinical Gastroenterology, 40: 101620.
Ford AC, Lacy BE, Talley NJ, 2017, Irritable Bowel Syndrome. New England Journal of Medicine, 376: 2566–2578.
Lin G, Wang J, Ge J, 2017, Practical Internal Medicine. People’s Medical Publishing House, Beijing.
Tang C, Zhang S, 2015, Internal Medicine, Digestive Medicine. People’s Medical Publishing House, Beijing.
Yu J, Lao H, 2012, Observation on the Therapeutic Effect of Berberine Combined With Compound Glutamine in the Treatment of 36 Cases of Diarrhea-Predominant Irritable Bowel Syndrome. Journal of Guangdong Medical College, 30(4): 427–428.
Osadchiy V, Martin CR, Mayer EA, 2019, The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clinical Gastroenterology and Hepatology, 17(2): 322–332.
Jiang T, Niu R, Liu Q, et al., 2022, Effects of Wenshen Jianpi Prescription on Visceral Sensitivity and c-Fos Expression in Rats With Diarrhea-Type Irritable Bowel Syndrome With Spleen and Kidney Yang Deficiency Based on “Gut–Brain Interaction”. Chinese Journal of Traditional Chinese Medicine Information, 29(10): 96–102. DOI:10.19879/j.cnki.1005-5304.202202209.
Feng W, Wu H, Luo C, 2016, Effects of Traditional Chinese Medicine on c-Fos Expression in Irritable Bowel Syndrome. Chinese Journal of Traditional Chinese Medicine, 34(10): 2343–2345. DOI:10.13193/j.issn.1673-7717.2016.10.010.
Li Q, Su H, Chen Z, et al., 2023, Observation on the Efficacy of Linaclotide Combined With Xiaoyaosan in the Treatment of Constipation-Type Irritable Bowel Syndrome and Its Effect on Plasma 5-HT and VIP. Chinese Journal of Traditional Chinese Medicine and Pharmacy, 30(5): 898–900.